SCHEMBL22249092

SCHEMBL22249092

CC(C)(C)n1ncc(OCc2ccc(-c3ccc(COCCF)cc3)cc2)c(Cl)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
GALR3 O60755 1/20 0.43
NR2F2 P24468 1/20 0.43
GPR183 P32249 1/20 0.43
KMT2A Q03164 1/20 0.43
GPR35 Q9HC97 1/20 0.43
HTT P42858 2/20 0.41
HPGD P15428 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.39
MAPK1 P28482 3/20 0.36
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
ITGB7 P26010 1/20 0.36
MAPK14 Q16539 5/20 0.36
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flurpiridaz SCHEMBL1628419 0.97 SMN1; SMN2 (0.45) SMN1; SMN2LMNANPC1RAB9AMEN1
Flurpiridaz F 18 SCHEMBL12453262 0.97 SMN1; SMN2 (0.45) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL16901904 0.90 SMN1; SMN2 (0.43) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL16903760 0.89 SMN1; SMN2 (0.43) SMN1; SMN2LMNANPC1RAB9AMEN1
Flurpiridaz SCHEMBL16901966 0.88 SMN1; SMN2 (0.42) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL15596646 0.88 SMN1; SMN2 (0.42) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL15566349 0.88 SMN1; SMN2 (0.49) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL1629038 0.88 SMN1; SMN2 (0.45) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL18672268 0.88 SMN1; SMN2 (0.46) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL15596698 0.88 APP (0.48) SMN1; SMN2LMNANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 SMN1; SMN2 699/4885LMNA 1449/4885NPC1 221/4885
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents FABP3, TNNI3, TNNT2 SMN1; SMN2 699/4885LMNA 1449/4885NPC1 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.